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Current evidence is reviewed here on risks and benefits of estrogen and progestin use by 
peri- and postmenopausal women in relation to the following conditions: endomettial can- 
cer, breast cancer, osteoporosis, and coronary artery disease (CAD). On balance, estrogen 
therapy appears to be beneficial for menopausal women, as it probably reduces the risks of 
CAD and osteoporosis, two of the major causes of mortality and morbidity. Although 
unopposed estrogen therapy increases the risk of endometrial cancer, that cancer is rela- 
tively rare and is not fatal in the vast majority of cases associated with estrogen use. 
Definitive conclusions about the relation of menopausal estrogens to breast cancer cannot 
be drawn due to inconsistent evidence to date. Although evidence from randomized con- 
trolled trials is lacking, biochemical and clinical evidence suggest that progestin supplemen- 
tation is associated with a reduction in endometrial cancer risk in women taking menopausal 
estrogens. Progestin supplementation also may augment the beneficial effects of estrogens 
in providing protection against osteoporosis, although this effect is not yet well established. 
There is little direct evidence bearing on the relation of menopausal progestins to breast 
cancer. Although studies of CAD per se are lacking at present, progestins probably unfa- 
vorably alter lipoprotein profiles, thereby increasing a user’s risk of CAD. Given the rela- 
tively high incidence and mortality of CAD in postmenopausal women, any negative effects 
on CAD risk could potentially counterbalance beneficial effects on other causes. We con- 
clude that estrogen replacement therapy is of potential benefit to postmenopausal women, 
but that the question of progestin supplementation requires further study, particularly for 
CAD risk. 0 1988 Academic Press, Inc. 
INTRODUCTION 
Considerable controversy surrounds the use of estrogens and progestins by 
peri- and postmenopausal women. Some risks and some benefits of menopausal 
i Based on a symposium by the same title held at the 10th Annual Meeting of the American Society 
of preventive Oncology, Bethesda, MD, 1986. 
* Supported in part by USPHS Grant PO1 CA 13556-15 from the National Cancer Institute, Bethes- 
da, MD. 
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hormone use have been clearly established. However, the risk-benefit equation 
cannot be formulated definitively at present owing to inadequate information in 
several key areas. This article reviews current evidence, prefaced by a brief 
discussion of recent trends in the prevalence of menopausal hormone use. 
Trends in Prevalence of Menopausal Hormone Use 
In the United States there was a dramatic increase in dispensed retail prescrip- 
tions for noncontraceptive estrogens between the mid-1960s and the early 1970s 
(90% of noncontraceptive estrogens in 1983 were used by women, and 56% of the 
associated diagnoses in women were related to aging, i.e., menopausal symptoms, 
senile vaginitis, and osteoporosis (66)). After reports of possible association with 
endometrial carcinoma (124, 154), sales of noncontraceptive estrogens dropped in 
1976 by almost 30%, with the greatest decline in the high-dose estrogen products. 
This downward trend continued until 1980. Since then, there have been annual 
increments in noncontraceptive estrogen prescriptions (66). Estrogen replacement 
therapy at menopause most commonly consists of conjugated natural estrogens 
(unlike the synthetic formulations in oral contraceptives). Recently, transdermal 
estrogen (estradiol) has been prescribed for postmenopausal women (75); howev- 
er, published reports of its safety and efficacy are too preliminary and will not be 
considered in this review. 
Trends in concomitant prescriptions of Premarin (the conjugated estrogen most 
frequently prescribed for menopausal women) with Provera (the most frequently 
prescribed progestin) showed steady increases between 1980 and 1983 (66). Since 
1983, the upward trends have continued, with progestin supplementation of es- 
trogen prescriptions becoming increasingly more common (Dianne L. Kennedy, 
FDA, personal communication). Progestins (or progestogens) include the natural 
hormone (progesterone) and synthetic derivatives. Menopausal women in the 
United States receive the synthetic derivatives. Although there are a great many 
synthetic formulations with widely varying therapeutic effects, the most com- 
monly prescribed forms are the 19-not-testosterone derivatives (e.g., norethin- 
drone) and the hydroxyprogesterone derivatives (e.g., medroxyprogesterone ac- 
etate). In the United States in 1983, of all oral noncontraceptive progestin pre- 
scriptions, about 11% were for norethindrone and 89% for medroxyprogesterone 
(including Provera). This distribution may not exactly reflect the experience of 
menopausal women because progestins are given for a number of conditions other 
than menopausal symptoms. 
ESTROGENS 
Estrogen replacement therapy has long been known to protect against the oc- 
currence of such menopausal symptoms as hot flashes and vaginal dryness and 
itching. The greatest concern about risks associated with menopausal estrogens 
has focused on endometrial and breast cancers. 
Endometrial Cancer: Increased Risk 
For 1987, the American Cancer Society has estimated that there were 2,900 
deaths and 35,000 new cases of endometrial cancer in the United States (3). The 
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disease generally presents with vaginal bleeding, is usually diagnosed at an early 
stage, and has a favorable prognosis (i.e., 92% 5-year relative survival among 
white women with Stage I disease and 84% for all stages combined) (95). The 
average annual age-adjusted incidence rate was higher in 1978-1981 for white 
(25.1 per 100,000 population) than for black (13.4 per 100,000) (139) women. 
The magnitude of increase in reported endometrial cancer incidence rates in the 
late 1960s and early 1970s suggested that a change might have occurred in the 
nature or frequency of exposure to a causative environmental agent (145). The 
inference about the likely determinant for this incidence pattern was revealed in 
1975 with the publication of two case-control studies showing four- to sevenfold 
relative risk estimates for the association of estrogen replacement therapy with 
endometrial cancer (124, 154). These reports were followed by a succession of 
epidemiologic studies that demonstrated elevated relative risks and dose- 
response relationships associated with estrogen use (Table 1). 
Following the declining trend in estrogen prescriptions during the late 197Os, 
endometrial cancer incidence rates diminished (7, 143). Although the incidence of 
endometrial cancer increased in the early 197Os, the concurrent age-adjusted mor- 
tality rates remained relatively stable between 1973 and 1981 (95). The stable 
mortality in the context of rising incidence may be attributed to a general trend 
toward improving survival in the population and to the fact that a significant 
proportion of cases among estrogen users were early-stage lesions (26) (Table 2). 
Duration of estrogen use and cumulative dose are major predictors of endo- 
metrial cancer risk (6, 41, 57, 58, 65, 85, 90, 120, 121, 129, 146). One year of use 
is probably the minimum exposure associated with increased risk (90, 129), al- 
though some studies have reported an increase in risk only with 3 or more years 
of use. 
Following cessation of use, the period of time after cessation of use required 
before elevated risks approach those of the nonuser has not been determined 
precisely. Some studies have described short time intervals of 6 months to 2 years 
(57, 85), whereas one multi-hospital casecontrol study reported persistently in- 
creased risks up to 10 years after cessation of use (121). The data comparing 
trends of estrogen prescription volume with endometrial cancer incidence rates 
during the late 1970s are more consistent with the evidence for a relatively short 
time interval between cessation and decline in endometrial cancer risk (7). 
These epidemiologic data have resulted in important changes in patient man- 
agement (4). First, lower doses of estrogen, such as the 0.625-mg daily dosage, are 
being prescribed, and cyclic therapy is generally recommended, with 1 week of 
each 4-week cycle to be estrogen-free. Second, progestins are frequently being 
added during the last 10 days of the estrogen cycle to counteract the proliferative 
effects of estrogens on the endometrium (see below for the benefits of progestins). 
Third, physicians are more apt to wean women off hormone therapy after some 
months or a few years of use to avoid the elevated risks that occur with increasing 
duration of use. The effort to minimize duration of use runs contrary to the 
optimal regimen for the prevention of osteoporosis and associated fractures. The 
potential for causing endometrial cancer may be diminished through careful ad- 
ministration of the minimal therapeutically effective dose of estrogen, in conjunc- 
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TABLE 2 
AGE-ADJUSTED INCIDENCE, MORTALITY, AND SURVIVAL FOR UTERINE CORPUS CANCER, 
WHITE FEMALES, UNITED STATES 
5-Year 
Incidence/ Mortality/ relative 
Year 100,000 Year 100,000 Year survival 
1969 22.6 
1971 24.6 
1973 29.0 1973-1977 1.9 1970-1973 81% 
197.5 32.4 
1977 28.5 
19711981 25.1 1978-1981 2.1 1974-1979 87% 
Sources: SEER Cancer Incidence and Mortality in the United States, 1973-1981, and “Cancer Rates 
and Risks,” 3rd ed. National Institutes of Health, Bethesda, MD, 1985. 
Breast Cancer: Inconsistent Evidence 
In Western Europe and North America, breast cancer represents the most 
frequent cancer in women, excluding the incidence of nonmelanoma skin cancers. 
In these countries, breast cancer accounts for about 4% of all deaths, 20% of all 
cancer deaths, and 25% of all cancer cases in women, For 1987, the American 
Cancer Society estimated that there were 130,000 new cases and 40,900 deaths 
from breast cancer (3). 
As the evidence for a causal relationship of noncontraceptive estrogen replace- 
ment therapy with endometrial cancer became apparent, there was increased 
interest in determining a potentially similar relationship of estrogens and breast 
cancer. The assumption seemed reasonable because of estrogen receptor activity 
and estrogen dependency in both target organs and because both cancers seem 
estrogen dependent. Moreover, endometrial and breast cancers share some hor- 
monally related risk factors (e.g., nulliparity). 
The case-control studies of breast cancer published before 1980 that had spe- 
cifically considered estrogen use were uniformly negative (55). Two cohort stud- 
ies suggested an association; one, in particular, showed an increased risk among 
exposed women only after 10 years of follow-up (51). 
Since 1980, several case-control studies have been reported (9, 48, 50, 56, 62, 
64, 115, 151), and at least one prospective study (37) has appeared in various 
versions in several journals. That study purported to show a reduced breast can- 
cer risk among estrogen-exposed women compared with those not exposed. 
Ten case-control studies published since 1980 are summarized in Table 3. Some 
were population-based, while others relied on hospitalized control groups. Many 
geographic areas within the United States and elsewhere were represented. Most 
provided analyses separately for pre- and postmenopausal women and for natural 
versus surgical menopause; one was limited to women under age 55 (150, 151). 
Most authors chose to examine data separately for women who had had bilateral 
oophorectomy from those who had undergone a natural menopause, which is 
appropriate in that the two groups differ with respect to their risk of breast cancer 
and endogenous estrogen levels. The accumulated knowledge from these studies 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































208 ERNSTER ET AL. 
noted an increased risk for breast cancer associated with estrogen use, whereas 
Kelsey (64), Hulka (56), Hiatt (48), Wingo (150, 151), Kaufman (62), and their 
respective coauthors reported no elevation in risk. Ross et al. (115) showed an 
increased breast cancer risk for women who had undergone a natural menopause. 
Brinton et al. originally suggested that increased risk occurred primarily among 
those whose menopause occurred as a result of bilateral oophorectomy (9), but 
based on a later analysis (10) of their expanded case-control data, the authors 
found no significant elevations in risk associated with ever use of menopausal 
hormones in any of the menopause groups studied (natural, ovaries retained, and 
ovaries removed). As noted below, however, they did find an elevation in risk 
associated with long-term use. 
In most studies, protracted estrogen use did not show the risk enhancement that 
was observed with endometrial cancer. None of these studies summarized in 
Table 3 reported a significant duration effect, with the exception of the expanded 
analysis of Brinton et al. (10) which showed an increase in risk with use duration 
across the menopausal groups studied; use of menopausal estrogens for 20 or 
more years was associated with a 50% increase in risk. The suggestion of a dose 
effect appears, however, in several of the studies. Ross et al. (115) demonstrated 
increasing risk with increasing doses. Hoover et al. (50) and Hiatt et al. (48), 
whose data on estrogen use were based on medical records, showed increased 
relative risks with increased number of prescriptions, a proxy indicator for inten- 
sity of estrogen use. Hulka et al. (56) found an increased risk with injectable 
estrogen; parenteral administration delivers high circulating levels of biologically 
active doses to the target organs, because it bypasses the enterohepatic circula- 
tion and hepatic deactivation. Brinton et al. reported an increased risk of breast 
cancer with increasing estrogen dose in their original analysis (9), but this was not 
confirmed in their expanded analysis (10). Kelsey et al. (64) found no association 
of breast cancer and milligram-months of estrogen use; nor was an association 
demonstrated in the Wingo er al. (151) and Kaufman et al. (62) studies that 
assessed estrogen dosages. The finding of a dose-response relationship in some 
studies is noteworthy and would be supportive of a causal association, although 
the negative studies suggest caution in such an interpretation. 
Additional important risk factors for breast cancer are benign breast disease, in 
particular the subgroups with proliferative and atypical cell patterns, and family 
history of breast cancer. These factors generally weigh heavily with clinicians in 
decisions about prescribing estrogens. Epidemiologic studies, unless specifically 
designed to test the potential interactions of estrogens with one or another of these 
risk factors, usually contain insufficient numbers of subjects to produce reliable 
estimates of risk. Some authors (9, 10, 115, 136) have suggested that estrogens 
enhance breast cancer risk in women with prior benign breast disease, but two 
studies with the largest number of relevant subjects have shown no such associ- 
ation (62, 151). A similar equivocal statement could be made about the possible 
modifying effect of family history (9, 56). 
In summary, epidemiologic studies have not consistently demonstrated a causal 
link between estrogen replacement therapy and breast cancer risk. To the extent 
that such an association exists, it has been observed primarily with high-dosage 
estrogen, higher than the 0.625 mg of conjugated estrogens that is usually pre- 
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scribed daily to relieve menopausal complaints and retard development of os- 
teoporosis. However, even a high-dose effect was not observed in several large, 
well-designed epidemiologic studies that had sufficient power to detect an asso- 
ciation if one existed. 
Osteoporosis and Associated Fractures: Beneficial Effect 
A role for estrogen in the etiology of osteoporosis has been suggested by the 
many studies showing that loss of bone mass accelerates in women just after 
bilateral oophorectomy or natural menopause (21, 23, 54, 71, 88, 96) and by the 
finding that bilateral oophorectomy without estrogen replacement before natural 
menopause is associated with an increased risk for hip fracture (70). 
Many studies have also shown that estrogen replacement therapy at doses of at 
least 0.625 mg conjugated estrogen or 1.5 pg ethinylestradiol per day prevents or 
greatly retards bone loss in peri- and postmenopausal women as long as estrogen 
is being taken (23, 24, 32, 38, 52, 53, 79, 93, 107, 126). Doses below these levels 
afford partial protection (38, 53). Following cessation of estrogen use, bone loss 
occurs at a rate similar to that seen immediately after the menopause in women 
not treated (25, 82). Results from a randomized trial of an estrogenlprogestogen 
treatment versus a placebo in 94 women who were 6 months to 3 years postmeno- 
pausal are shown in Fig. 1 (24). After 2 years of estrogen/progestogen use, some 
of the women were randomly switched from placebo to treatment and others from 
treatment to placebo. The preservation of bone mass while on estrogen/ 
progestogen treatment was noted both among those initially assigned to the treat- 
ment and among those who started treatment after 2 years. Similarly, the loss of 
bone mass while on placebo was seen among those initially assigned to placebo 
and among those assigned to placebo after 2 years on treatment (Fig. 1). 
Estrogen replacement therapy also protects against fractures associated with 
osteoporosis. Several case-control studies (59, 61, 71, 100, 147) have reported 
that estrogen replacement therapy by peri- or postmenopausal women reduces the 
. A.* = placebo 00~ estrogenlgestagen 
41 , Study I , 1 Study n 1 
0 6 12 16 24 30 36 
Months 
FIG. 1. Bone mineral content (BMC) of the distal forearm as a function of time 
(Study I) and 77 (Study II) women soon after menopause (24). 
and treatment in 94 
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risk for hip and Colles’ fractures by about 50% while the estrogens are being 
taken. The two case-control studies (100, 147) that considered the effect of dose 
showed no difference in the degree of protection according to dose. Table 4 shows 
that, in general, the longer the use, the lower the risk-at least through 6 years of 
use. Some evidence (147) suggests that much of the protective effect is lost within 
a few years of stopping estrogen therapy. Replacement estrogens also reduce the 
risk of vertebral fractures (32, 39, 81, 109). 
Thus, studies consistently show that estrogen replacement therapy protects 
against osteoporosis and associated fractures while the estrogens are being taken. 
However, several details of the relationship remain to be elucidated. First, since 
bone loss appears to accelerate around the time of menopause, some would argue 
that the shorter the interval between onset of menopause and initiation of estrogen 
use, the more bone mass is preserved (2). Two case-control studies of hip fracture 
(59, 70), in fact, suggest that use close to the time of menopause affords greater 
protection than the same extent of use in later years. However, if bone loss 
accelerates immediately after cessation of use to an extent similar to that imme- 
diately following menopause (25, 82), this argument for the importance of starting 
estrogen therapy immediately after the menopause is not compelling, unless es- 
trogens are to be taken indefinitely. Studies of the extent to which estrogens 
started several years after menopause retard bone mass loss are needed. Second, 
the optimal dose of estrogen for maximum benefit is uncertain; evidence is con- 
tradictory as to whether doses greater than 0.625 mg of conjugated estrogens or 
1.5 pg of ethinylestradiol bring about a further increase in cortical bone mass or 
decrease in fracture risk (23, 38,52,53,79,93, 100, 104, 147). Third, whether the 
addition of cyclic progestogen to the estrogens is more beneficial than estrogens 
alone, as suggested by short-term trials (24, 25), remains to be determined in 
long-term trials. Effects of progestogens will be discussed in greater detail below. 
Fourth, the finding of Weiss ef al. (147) that the protective effect of estrogen 
replacement therapy against hip and forearm fractures is lost within a few years 
after cessation of use needs to be evaluated in other studies, since (as Weiss et al. 
point out) numbers of former users were small in their studies. Also, one would 
expect that prevention or retardation of bone loss, even temporarily, would result 
in greater ultimate preservation of bone mass than if loss had continued unabated. 
TABLE 4 
RELATIVE RISK OF FRACTURE OF THE HIP OR LOWER FOREARM ACCORDING TO DURATION OF USE 
OF POSTMENOPAUSAL ESTROGEN 
Duration of use 
(years) 













Coronary Artery Disease: Probable Beneficial Effect 
211 
Cardiovascular diseases (CVDs) are by far the leading cause of death among 
U.S. women as well as men (140). Thus, even minor changes in CVD risk as a 
result of estrogen replacement therapy could affect life expectancy in large num- 
bers of women, easily outweighing the effects of changes in risk of other, less- 
common diseases. Most studies report that estrogen replacement therapy protects 
against CVD and, in particular, against coronary artery disease (CAD) among 
women (Table 5). Of 19 studies, 15 show a reduction in risk among estrogen users 
(1, 13, 20, 45, 47, 73, 86, 94, 102, 103, 105, 116, 131, 133, 134); two studies show 
no effect (113, 114), and two report an increased risk (60, 149). 
In the studies showing a protective effect, the estimated relative risk in estrogen 
users compared with nonusers varies from about 0.2 to 0.7. Of the two reports 
showing no effect of estrogen use on CVD risk, one (114) was of women under 50 
years of age, who-because of their young age-had experienced infrequent use 
of estrogen replacement therapy and were at minimal risk for CVD. Only a small, 
flawed case-control study (60) and the Framingham Study (149) have reported an 
increased risk for CVD among estrogen users (Relative risk [RR] = 8.44 and 1.76, 
respectively). The case-control study suffered from various methodologic prob- 
lems (14), and a reanalysis (30) of the Framingham data using more specific 
TABLE 5 
STUDIES OF ESTROGEN REPLACEMENT THERAPY AND CARDIOVASCULAR DISEASE 






Lafferty et al. (73) Cohort MI 0.16 b 
MacMahon (86) Cohort All CVD 0.30 b 
Stampfer el al. (131) Cohort All CVD 0.30 0.2-0.6 
Nachtigall et al. (94) Trial MI 0.33 b 
Hammond et al. (45) Cohort All CVD 0.33 b 
Potocki (105) Cohort All CVD 0.33 b 
Bush et al. (15, 16) Cohort CVD deaths 0.34 0.1-0.9 
Talbott et al. (134) Case-Control Sudden death 0.34 0.1-3.2 
Burch et al. (13) Cohort Fatal CAD 0.43 0.24.7 
Ross et al. (116) Case-Control Fatal CAD 0.43 b 
Petitti er al. (102) Cohort CVD deaths 0.50 0.2-0.9 
Henderson et al. (47) Cohort MI 0.54 b 
Szklo et al. (133) Case-Control Nonfatal MI 0.61 0.2-1.9 
Adam et al. (1) Case-Control Fatal MI 0.65 0.5-0.9 
Pfeffer et al. (103) Case-Control MI 0.68 0.3-l .4 
Rosenberg et al. (113) Case-Control Nonfatal MI 0.97 0.5-2.0 
Rosenberg et al. (114) Case-Control Nonfatal MI 1.00 0.6-1.7 
Wilson et al. (149) Cohort All CVD 1.76 b 
Jick et al. (60) Case-Control Nonfatal MI 8.44 4.6-12.3 
0 MI, myocardial infarction; CVD, cardiovascular disease; CAD, coronary artery disease. 
b Relative risk cannot be computed from available published data. 
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endpoints showed a protective effect of estrogen use among women 50-59 years 
(RR = 0.32), and no adverse effects among women 60 years and older (RR = 1.1). 
Data on estrogen dose, duration of use, and type of estrogen used in relation- 
ship to CAD are generally unavailable in the published reports. Thus, it is unclear 
whether dose and length of use affect risk. However, some reports showed that 
women currently using estrogens had a lower risk of CAD than women who had 
previously used them (93,116,13 1). Effects of recency of use, dose, length of use, 
age at time of use, and type of compound used are important issues meriting 
further study. 
It is biologically plausible that estrogen replacement therapy protects against 
the development of CAD. Serum high-density lipoprotein (HDL) is a strong, 
inverse predictor of CAD, and estrogen use has been shown to raise serum levels 
of HDL (18, 111, 144). In one report (17), women using moderate doses (0.625 mg) 
of oral conjugated estrogens had HDL levels approximately 17% higher than 
women not taking estrogens. Theoretically, this magnitude of increase in HDL 
levels would correspond to about a 40% reduction in CVD risk. 
Oral estrogens tend to reduce low-density lipoprotein (LDL), the atherogenic 
subfraction of total cholesterol. In the study (17) cited above, estrogen users had 
LDL levels approximately 7% lower than those of nonusers. Such difference in 
LDL levels would theoretically correspond to about a 3% reduction in CVD risk 
among women. 
PROGESTINS 
To date, relatively few studies of the long-term health effects of menopausal 
progestational agents have been undertaken. Clinical and biochemical evidence 
would suggest that progestins counter the adverse effects of estrogens on the 
endometrium. The published studies of the relation of progestins to breast cancer 
risk do not permit conclusions to be drawn at this time. Indeed, long-term use, 
namely for about 2 years or longer, of combination oral contraceptives with rel- 
atively high progestin content (i.e., formulations with the equivalent of 2.5 mg or 
more of norethindrone acetate) reduces the risk of benign breast disease about 50 
to 60% (130). As reviewed below, some evidence suggests that progestins given 
alone can prevent or arrest bone loss, similar to estrogens, and that cyclic pro- 
gesterone coupled with estrogen may further increase bone mass, at least in the 
short term. Considerable concern has been voiced over the potential adverse 
effects of progestins on CVD, mediated by unfavorable changes in lipoprotein 
fractions associated with progestin use. 
Endometrial Cancer: Beneficial Effect of Progestin in Women 
Taking Estrogens 
Estrogen is a growth hormone for endometrial tissue. During the first half of al 
normal menstrual cycle (proliferative phase), estrogen activates special intracy- 
toplasmic proteins in the endometrial cells. These special proteins or receptors 
bind estrogen with a high affinity. Each endometrial cell may contain 5,000 to 
15,000 of these receptors. The activated estrogen receptor complex stimulates1 
new cell proliferation, Synthesis of progesterone receptors in endometrial cells is 
CLINICAL PERSPECTIVES 213 
largely dependent on estrpgen stimulation. Without the prior estrogen priming, 
progesterone has little activity on endometrial cells. Progesterone also inhibits 
estrogen receptor activity as well as the synthesis of progesterone binding sites (5, 
40, 46, 69, 89). 
Without the addition of progesterone and conversion from proliferative to 
secretory pattern, the endometrium has a tendency to shed in an irregular and 
unpredictable fashion. Continued unopposed estrogen stimulation produces the 
histologic pattern of hyperplasia, which has been shown to advance to adeno- 
matous hyperplasia, carcinoma in situ, or eventually to endometrial cancer (12, 
34, 42, 44, 84, 101). This progression is well recognized in patients with Stein- 
Leventhal syndrome (125) and patients with estrogen-producing tumors (43). An 
elevated risk for endometrial cancer has also been reported in infertile women 
with disorders characterized by unopposed estrogen production (112). The daily 
addition of potent synthetic progestogens to the estrogen-primed endometrium 
produces a markedly altered endometrial response (135). This type of endo- 
metrium has a decidual pattern with a tendency to atrophy rather than progress to 
hyperplasia. 
The ability of potent progestogens to produce progressive endometrial atrophy 
has led to their use as therapeutic agents (67, 68, 148). In addition to their ability 
to convert adenomatous hyperplasia to normal endometrium, pharmacologic 
doses of progestogens may be used to treat metastatic adenocarcinoma of the 
endometrium; this will produce objective regression of the lesions in approximate- 
ly 30% of patients (33, 108). 
Although the evidence for a protective effect of cyclical progestogens in reduc- 
ing the risk for endometrial neoplasia is compelling, no firm conclusions regarding 
the most effective progestogen and dosage regimen can be drawn. One commonly 
suggested regimen is 10 mg of medroxyprogesterone acetate orally for the last 10 
days of each cycle. When this progestogen is prescribed in peri- and postmeno- 
pausal women 50-60 years of age receiving 0.625 mg conjugated estrogens orally, 
97% will experience a 3- to 4-day “menstrual flow.” This proportion decreases 
with increasing age so that by age 65, 60% continue to experience light bleeding 
(36). This persistent bleeding during the sixth and seventh decades of life is ob- 
jectionable to some women, making compliance a potential problem even among 
women who may appreciate the therapeutic benefits of this regimen. With estro- 
gen alone, however, the bleeding is less predictable and therefore also potentially 
problematic. 
Breast Cancer: An Open Question 
Several lines of epidemiologic evidence suggest a protective effect of progestin 
for breast cancer. Women with a history of infertility due to endogenous proges- 
terone deficiency were at increased risk of premenopausal (not postmenopausal) 
breast cancer compared with women whose infertility was due to nonhormonal 
causes in one study (27), and women with infertility due to conditions causing 
unopposed estrogen production were found to have a nonsignificant excess of 
breast cancer compared to women in the general population in another study 
(112). In addition, breast cancer risk has been reported to be inversely related to 
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plasma progesterone levels (92, 118). The preliminary results of an international 
study showed that progestins administered as injectable contraceptives (depot 
medroxyprogesterone acetate) were associated with a decreased breast cancer 
risk (152). Finally, in a nested case-control study, risk for benign breast disease 
was shown to be inversely related to progesterone dose in oral contraceptives 
(11). 
On the other hand, conflicting evidence is derived from several sources. Epi- 
demiologic investigations have failed to find any evidence of differences in men- 
strual cycle irregularity among women with breast cancer compared with controls 
(122) nor differences in luteal phase progesterone levels in women with a history 
of benign breast disease or breast cancer compared with healthy premenopausal 
parous women (106). A study that followed 5,000 women receiving injections of 
medroxyprogesterone for contraception for 4 to 13 years did not exhibit any 
alteration in breast cancer risk (78). Moreover, the large-scale Contraceptive and 
Steroid Hormone (CASH) study found no relation of progestogen “potency” of 
oral contraceptives to breast cancer (130), following an earlier report that breast 
cancer risk was positively related to the progestin “potency” of oral contracep- 
tives (104, 132). 
One widely reported prospective study (35, 37) suggested that women taking 
postmenopausal estrogen with progestin had a markedly reduced risk for breast 
cancer compared with women taking estrogens alone or untreated women. The 
study has been criticized for failure to describe and adjust for important differ- 
ences among women in the various treatment groups (31, 77). Since it was not a 
randomized study, women whom physicians chose to treat with progestins may 
have differed from other women with regard to family and personal history of 
breast disease and other breast cancer risk factors. A small clinical trial by Nachti- 
gall et al. (94) also showed lower breast cancer incidence among women receiving 
high-dose conjugated estrogens cyclically with progesterone (O/84), when com- 
pared with control women (4/84). 
Although some data on endogenous progestins and on exogenous progestins in 
oral contraceptives support the notion that progestins may play a protective role, 
the evidence is not consistent, and there are no carefully designed, large-scale 
studies of the potential causal role of exogenous menopausal progestins in breast 
cancer. At present the evidence would at least suggest that the addition of cyclical 
progestins to menopausal estrogens will have no adverse affects on breast cancer 
risk. 
Osteoporosis and Associated Fractures: Probable Beneficial Effect 
The few available studies of the role of progestins in osteoporosis have been 
based upon limited sample size, and none have addressed the question of long- 
term effects. On balance, however, they suggest a beneficial effect. Some evi- 
dence indicates that progestins given alone confer protection against osteoporosis 
(29,83, 119), and that combined estrogen/progestin regimens have a greater effect 
than estrogen alone by promoting new bone formation (24,25,28,93, 110). There 
is no evidence that adding progestins to estrogens negates the beneficial effects of 
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estrogen given alone. More research is needed of possible differential effects on 
bone matrix and mineralization by type of progestin administered (80). 
Coronary Artery Disease: Potential Increased Risk 
The effects of progestins on risk of CAD may be the unresolved issue of greatest 
potential importance in the menopausal replacement hormone risk-benefit equa- 
tion. The issue is unresolved because studies of the relationship of menopausal 
hormones to CAD have been largely limited to unopposed estrogens and have not 
evaluated the effect of progestin supplementation. However, women who take 
oral contraceptives that contain relatively high doses of the progestins norethin- 
drone acetate and norgestrel have been reported to be at increased risk for my- 
ocardial infarction or stroke compared with women who take lower dose formu- 
lations (63, 91). 
Serum lipoproteins, a major predictor of CVD risk, appear to be adversely 
affected by progestins. A variety of studies have shown that progestins are asso- 
ciated with increases in LDL and decreases in HDL. Such effects have been 
reported for unopposed progestins, for progestins combined with estrogens in 
various formulations of oral contraceptives (8, 142), and for progestins given to 
postmenopausal women as a supplement to estrogen replacement therapy (74,99, 
142); the extent of change in lipoproteins was dependent on the type of progestin 
administered. The vast majority of progestins prescribed for menopausal women 
are either medroxyprogesterone acetate (Provera), a 17a-hydroxyprogesterone 
derivative, or the 19-not-testosterone derivatives, mainly norgestrel and norethis- 
terone. Unopposed 19-nor derivatives decrease HDL cholesterol levels substan- 
tially, and modestly increase LDL cholesterol levels (72, 123, 143). Although 
some studies suggest that medroxyprogesterone acetate taken alone may decrease 
HDL cholesterol levels (123, 138), other investigators have concluded that use of 
this progestin does not result in the adverse lipoprotein profiles associated with 
the 19-nor derivatives (127, 128). When the 19-nor agents are added to estrogens, 
HDL levels are reduced below baseline, i.e., levels are lower than those in women 
not receiving estrogens (49, 87, 98, 153). When medroxyprogesterone acetate is 
added to estrogens, the HDL levels approach those of women not receiving es- 
trogens (97, 98, 141). One study, however, showed similar reductions in HDL 
associated with both levonorgestrel, a 1Pnor agent, and medroxyprogesterone 
acetate (99). A randomized clinical trial of women receiving the progestin nor- 
ethisterone acetate with estrogens and women on placebo found no differences in 
serum HDL cholesterol levels, which the authors suggested might be explained by 
the much lower progestin dose in their study (1 mg/day for 10 days) compared with 
previous investigations (22). Still, the favorable increase in HDL cholesterol usu- 
ally seen with estrogens given alone was not observed. 
Taken together, the above findings have led some investigators to conclude that 
progestin doses should be kept to the minimum possible to reduce endometrial 
cancer risk associated with unopposed estrogen use, or that they be avoided, 
especially among women who have had a hysterectomy (18) or those who have 
significant hyperlipidemia (137). Whether the adverse changes in lipoprotein lev- 
els associated with progestin use translate into an increased risk for CAD, and 
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whether that risk is sufficient to outweigh any benefits that accrue by adding 
progestins to menopausal estrogen therapy are areas that require careful study. 
SUMMARY 
On balance, for the diseases considered here, estrogen therapy appears to be 
beneficial for menopausal women, as it probably reduces the risks for CAD and 
osteoporosis, two of the major causes of mortality and morbidity among post- 
menopausal women. Although unopposed estrogen therapy increases risk for en- 
dometrial cancer, that cancer is relatively rare and is not fatal in the vast majority 
of cases associated with estrogen use. Definitive conclusions about the relation of 
menopausal estrogens to breast cancer cannot be drawn. The evidence is incon- 
sistent, and if there is any increase in risk associated with use, it is likely to be 
small and to apply only to use of high-dose preparations (>0.625 mg). For the 
most part, the higher-dose preparations should not be necessary for clinical relief 
of menopausal symptoms, to favorably affect CAD risk, or for prevention of 
osteoporosis. 
There is considerably less consensus on the issue of menopausal progestins. 
Although evidence from randomized controlled trials is lacking, biochemical and 
clinical evidence suggests that progestin supplementation is associated with a 
reduction in endometrial cancer risk among women taking menopausal replace- 
ment estrogens. Progestins may augment the beneficial effects of estrogens in 
providing protection against osteoporosis, although this effect is far from certain 
at this time. For breast cancer, there is little direct evidence bearing on either a 
causal or protective role of menopausal progestins. 
However, progestins probably unfavorably alter the lipoprotein profile, which 
may increase a user’s risk for CAD, although studies of CAD outcomes are 
lacking at present. Without knowing the effect of progestin supplementation on 
CAD, it would be inappropriate to draw any firm conclusions regarding its adop- 
tion at this time. Given the relatively high incidence and mortality of CAD in 
postmenopausal women, even a minor increase in risk, or negation of the benefits 
associated with unopposed estrogens, would not only cancel but also dramatically 
outweigh the “benefits” of progestins for other much less common diseases, most 
notably endometrial cancer. In terms of absolute numbers of lives affected, any 
negative effects on CAD risk could potentially counterbalance or displace the 
beneficial effects on all other causes combined. 
We conclude that moderate-dose estrogen replacement therapy is of potential 
benefit to postmenopausal women, but that progestin supplementation requires 
further study, particularly for CAD risk, before conclusions regarding its use can ; 
be drawn. Caution would dictate that if progestins are prescribed, the lowest 
doses possible to achieve desired effects on the endometrium should be used, with 
preference given to medroxyprogesterone acetate over the 1Pnor steroidal 
agents. Recommendations for individual patients may vary depending on their 
risk characteristics, including, among others, family history, lipid profiles, and 
hysterectomy status. Since there is wide variation in biologic activity among the 
various progestational agents, future studies should examine the effects on dis- 
ease by type of progestin, dose, and route of administration. 
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